Chiasma Reports Second Quarter 2018 Results
09 août 2018 16h05 HE
|
Chiasma, Inc.
Recent Highlights Include Completion of Enrollment of MPOWERED Phase 3 Trial and 50% Randomization in CHIASMA OPTIMAL Phase 3 Trial WALTHAM, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc....
Chiasma Completes Enrollment of MPOWERED(TM) Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly
25 juil. 2018 16h05 HE
|
Chiasma, Inc.
Chiasma Anticipates Trial Completion in Q4 2019 and Release of Top-line MPOWERED Data by Early 2020 WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage...
Chiasma to Present on New Methodologies in Acromegaly Clinical Trial Design at 12th Acromegaly Consensus Conference
18 juin 2018 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Achieves 50% of Target Patients Randomized in CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly
14 juin 2018 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces FDA Agreement to Redefine Certain Secondary Endpoints in CHIASMA OPTIMAL Phase 3 Clinical Trial
14 mai 2018 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., May 14, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reports First Quarter 2018 Results
10 mai 2018 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reports Fourth Quarter and Year End 2017 Results
20 mars 2018 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Poster Presentation at ENDO 2018 on Study Design of Phase 3 Double-Blind Trial Evaluating Oral Octreotide Capsules Versus Placebo in Patients with Acromegaly
16 mars 2018 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., March 16, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma to Present at the Cowen and Company 38th Annual Health Care Conference
05 mars 2018 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Honors Patients, Researchers for Rare Disease Day 2018
28 févr. 2018 08h45 HE
|
Chiasma, Inc.
WALTHAM, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...